Diabetic Retinopathy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Diabetic Retinopathy Treatment Landscape. Click here to read more @ Diabetic Retinopathy Pipeline Outlook
Key Takeaways from the Diabetic Retinopathy Pipeline Report
On August 18, 2025 (Monday), findings published online in JAMA Ophthalmology (August 14 edition) revealed that semaglutide therapy in adults with diabetes does not raise the risk of developing eye disorders or diabetic retinopathy.
On August 15, 2025, Eyepoint Pharmaceuticals Inc. carried out a randomized, double-masked clinical trial assessing the ocular safety and efficacy of two different doses of the EYP-1901 IVT insert, compared with a sham treatment.
On August 18, 2025, Genentech Inc. initiated a clinical trial designed to investigate both ocular and systemic safety, tolerability, and efficacy of RO7446603 in patients with diabetic macular edema (DME). The study includes two main parts: Phase I (Parts 1–4), which examined the safety of single and multiple intravitreal (IVT) doses as monotherapy or in combination with IVT aflibercept or IVT faricimab (administered separately), and Phase II (Part 5) for further evaluation.
DelveInsight's Diabetic Retinopathy pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Diabetic Retinopathy treatment.
The leading Diabetic Retinopathy Companies such as Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
Promising Diabetic Retinopathy Pipeline Therapies such as Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others.
Discover groundbreaking developments in Diabetic Retinopathy therapies! Gain in-depth knowledge of key Diabetic Retinopathy clinical trials, emerging drugs, and market opportunities @ Diabetic Retinopathy Clinical Trials Assessment
Diabetic Retinopathy Emerging Drugs Profile
Tarcocimab tedromer: Kodiak Sciences
Tarcocimab is an investigational anti-VEGF therapy built on Kodiak's proprietary Antibody Biopolymer Conjugate (""ABC"") Platform and is designed to maintain potent and effective drug levels in ocular tissues for longer than existing available agents. Kodiak's objective with tarcocimab is to enable earlier treatment and prevention of vision loss for patients with diabetic retinopathy and to develop a new durability agent to improve outcomes for patients with retinal vascular diseases. Currently, the drug is in Phase III stage of its clinical trial for the treatment of diabetic retinopathy.
OTT166: Ocuterra Therapeutics
Nesvategrast (OTT166) is an investigational, novel, patented, potent and selective small molecule RGD integrin inhibitor designed with purpose engineering to have an optimum balance of physiochemical properties to allow it to distribute to the retina in high concentrations after topical (eye drop) administration to the eye. In preclinical studies, nesvategrast selectively inhibited key RGD integrin subtypes, including αvβ3, to regulate cellular responses to VEGF and other growth factors known to contribute to development and progression of diabetic retinopathy and other ocular diseases. In early clinical trials in patients with diabetic retinal disease, nesvategrast eye drops have demonstrated preliminary evidence of tolerability and biological activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diabetic retinopathy.
APX3330: Apexian Pharmaceuticals
APX3330 is a first-in-class, small molecule, oral inhibitor of the transcription factor regulator Ref-1 (reduction-oxidation effector factor-1). With a novel dual mechanism of action, APX3330 blocks the downstream pathways those involving angiogenesis (VEGF) and inflammation (NFkB) to decrease abnormal activation of both angiogenesis, and of inflammatory pathways that are implicated across several ocular diseases, including DR, DME, and age-related macular degeneration (AMD). APX3330 has shown a favorable safety and tolerability profile in 12 clinical trials conducted in healthy, hepatitis, cancer, and diabetic subjects. Currently, the drug is in Phase II stage of its clinical trial for the treatment of diabetic retinopathy.
OTX-TKI: Ocular Therapeutix
OTX-TKI is an investigational bioresorbable, hydrogel implant incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties, being evaluated for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diabetic retinopathy.
The Diabetic Retinopathy Pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Retinopathy with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Retinopathy Treatment.
Diabetic Retinopathy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Diabetic Retinopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Retinopathy market
Stay informed about the Diabetic Retinopathy pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Diabetic Retinopathy Unmet Needs
Diabetic Retinopathy Companies
Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Diabetic Retinopathy Pipeline Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Transform your understanding of the Diabetic Retinopathy Pipeline! See the latest progress in drug development and clinical research @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspectives
Scope of the Diabetic Retinopathy Pipeline Report
Coverage- Global
Diabetic Retinopathy Companies- Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
Diabetic Retinopathy Pipeline Therapies- Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others.
Diabetic Retinopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Diabetic Retinopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Dive deep into rich insights for new drugs for Diabetic Retinopathy Treatment, Visit @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspective
Table of Content
Introduction
Executive Summary
Diabetic Retinopathy: Overview
Pipeline Therapeutics
Therapeutic Assessment
Diabetic Retinopathy– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
KSI-301: Kodiak Sciences
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
RGX 314: Regenxbio Inc
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
OTX-TKI: Ocular Therapeutix
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Diabetic Retinopathy Key Companies
Diabetic Retinopathy Key Products
Diabetic Retinopathy- Unmet Needs
Diabetic Retinopathy- Market Drivers and Barriers
Diabetic Retinopathy- Future Perspectives and Conclusion
Diabetic Retinopathy Analyst Views
Diabetic Retinopathy Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
an hour ago
- CBC
What are Canada's four major cities? We put the Internet's heated debate to experts
Urban planning experts say there's a lot more to consider than just economic power and population.
Globe and Mail
3 hours ago
- Globe and Mail
Aircraft Actuators Market to Reach USD 13.73 Billion by 2030, Growing at a CAGR of 6.21%
"Aircraft Actuators Market" Mordor Intelligence has published a new report on the Aircraft Actuators Market offering a comprehensive analysis of trends, growth drivers, and future projections. Introduction The Aircraft Actuators Market plays a vital role in modern aviation, as actuators are key components that convert energy into motion to control various aircraft functions. They are essential for operating flight-control surfaces such as flaps, ailerons, rudders, and elevators, as well as systems like landing gear, braking, and even cabin seating. With the global aerospace sector expanding, the demand for reliable and efficient actuators continues to rise across commercial, military, and business aviation segments. Key Market Trends Electrification of Aircraft Systems: Electrical and electromechanical actuators are steadily replacing traditional hydraulic and pneumatic systems. This shift is linked to the aviation industry's focus on lighter components, reduced maintenance, and improved energy efficiency. More-electric aircraft designs are driving this adoption, with OEMs integrating electric actuators in secondary systems such as landing gear, thrust reversers, and flight surfaces. Strong Demand from Commercial Aviation: Commercial airlines remain the largest consumers of actuators, with backlogs in single-aisle programs like the Boeing 737 MAX and Airbus A320neo ensuring steady demand. These actuators are essential for flight-control functions such as ailerons, elevators, rudders, and flaps. The market benefits from continuous fleet expansion, rising air passenger traffic, and the replacement of aging aircraft with more efficient models. Aftermarket Expansion with Retrofit Opportunities: Airlines are increasingly investing in actuator retrofits to extend the operational lifespan of fleets. A key focus is on integrating health-monitoring sensors within actuator systems to enable predictive maintenance. These upgrades help reduce unscheduled downtime, optimize performance, and lower lifecycle costs, making the aftermarket segment an important growth area. Dominance of Linear Actuators: Linear actuators currently account for the majority of the market share due to their widespread use across primary flight controls, landing gear, and braking systems. Their strength lies in handling high-load applications that are central to safe aircraft operation. While rotary and other types are expanding, linear actuators are expected to remain dominant in the near term due to their reliability and established role. Market Segmentation By Type Linear Actuators – Widely used in flight-control surfaces, landing gear, and braking systems because they can handle heavy loads and provide precise linear motion. Rotary Actuators – Suitable for applications requiring rotational movement, increasingly important in tilt-rotor aircraft, eVTOLs, and adaptive wing designs. By System Hydraulic Actuators – Traditional systems valued for their ability to generate high force, especially in primary flight controls and landing gear. Electrical/Electromechanical Actuators – Growing segment favored for lighter weight, energy efficiency, and compatibility with more-electric aircraft. Pneumatic Actuators – Typically used in systems where moderate power and quick response are required, such as cabin doors or auxiliary applications. Mechanical Actuators – Basic actuators that rely on gears, levers, and other mechanical linkages, often used in secondary or backup applications. By Application Flight Control Surfaces – Largest segment, covering ailerons, elevators, rudders, and flaps, where actuators ensure safe and precise control. Landing Gear and Braking – Critical for retraction, extension, and braking systems, requiring high force and reliability. Fuel and Thrust Management – Involves actuators for regulating fuel flow, thrust reversers, and engine control systems. Cabin and Seat Systems – Actuators used in powered seats, adjustable cabin elements, and overhead bins, enhancing passenger comfort. Environmental and Utility Systems – Include actuators for systems such as air-conditioning, ventilation, and auxiliary functions inside the aircraft. By End User Commercial Aircraft – Dominant market segment driven by rising passenger traffic, fleet expansion, and OEM backlogs. Military Aircraft – Growing demand due to modernization programs, rotorcraft upgrades, and next-generation fighter development. General Aviation – Includes business jets and light aircraft, where compact and efficient actuators support both performance and comfort. By Fit OEM (Original Equipment Manufacturer) – Actuators supplied for newly manufactured aircraft, forming the bulk of initial demand. Aftermarket – Covers replacement, repair, and retrofit opportunities, driven by fleet maintenance, health-monitoring upgrades, and service life extensions. By Geography North America – Largest market, supported by Boeing, Bombardier, and strong US defense spending on fighter jets, helicopters, and UAVs. Europe – Driven by Airbus production and Eurofighter programs, with a shift toward electrical actuators in more-electric aircraft designs. Asia-Pacific – Fastest-growing region, led by China's COMAC C919, India's Tejas and AMCA, and expanding airline fleets across Asia. South America – Growth mainly from Embraer's regional jets in Brazil and steady airline fleet renewals across the region. Middle East & Africa – Aviation hubs in UAE and Qatar boost demand, while military programs and rising African air travel add opportunities Major Players Honeywell International Inc. – A leading aerospace technology company offering a wide range of actuator systems for flight control, landing gear, and cabin operations, with strong expertise in integrating smart monitoring solutions. Parker-Hannifin Corporation – Specializes in motion and control technologies, including hydraulic and electromechanical actuators, widely used in commercial, military, and business aircraft worldwide. Moog Inc. – Known for precision motion control products, Moog supplies advanced actuators for flight-control surfaces and military platforms, with a reputation for high reliability in critical aerospace systems. Safran SA – A global aerospace and defense group providing electrical and hydraulic actuator systems, particularly strong in European markets through partnerships with Airbus and other OEMs. Collins Aerospace (RTX Corporation) – Offers a broad portfolio of actuation solutions, from primary flight-control actuators to cabin systems, with strong global presence supported by its parent, RTX Corporation. Conclusion The Aircraft Actuators Market is set for steady growth, supported by rising aircraft production, expanding retrofit opportunities, and the shift toward electrified systems. Linear actuators remain the dominant segment, but electrical and rotary solutions are gaining traction as airlines and manufacturers embrace more-electric designs and new aircraft concepts. While North America continues to lead in market share, Asia-Pacific stands out as the fastest-growing region, driven by indigenous programs and fleet expansion. Industry Related Reports Aircraft Seat Actuation Systems Market: The Global Aircraft Seat Actuation Systems Market is analyzed in terms of revenue share and segmented by mechanism (linear and rotary), aircraft type (fixed-wing aircraft and helicopters), and geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa). The report provides market size and value forecasts in USD million across all these segments. Military Actuators Market: The Military Actuators Market is segmented by type (linear and rotary), system (mechanical, hydraulic, electrical, pneumatic), application (land, air, sea), and geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa). The report includes five years of historical data along with five-year market forecasts. Aircraft Landing Gear Systems Market: The Aircraft Landing Gear Systems Market is segmented by aircraft type (commercial aviation, military aviation, and general aviation), gear position (nose landing gear and main landing gear), material (high-strength steel alloys, titanium alloys, composites, and others), end user (OEM and aftermarket/MRO), and geography (North America, Europe, Asia-Pacific, and others). Market forecasts are presented in terms of value (USD). About Mordor Intelligence: Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics. For any inquiries or to access the full report, please contact: media@
CTV News
4 hours ago
- CTV News
U.S. health officials urge Kennedy to stop spreading vaccine misinformation
Hundreds of current and former employees of U.S. health agencies on Wednesday accused U.S. President Donald Trump's health secretary of putting them at risk by spreading false information. In an open letter, the federal officials criticized U.S. Health Secretary Robert F. Kennedy Jr. -- a noted vaccine skeptic -- nearly two weeks after an armed attack on the headquarters of the Centers for Disease Control and Prevention (CDC), the main U.S. health agency. A gunman who blamed the Covid-19 vaccine for sickening him targeted several buildings at the Atlanta-based CDC on August 8, killing a police officer. The attack 'was not random,' the signees of the open letter said, pointing to 'growing mistrust in public institutions, driven by politicized rhetoric that has turned public health professionals from trusted experts into targets of villainization -- and now, violence.' Kennedy, who has repeatedly aired false information about vaccines and slammed the agencies he heads as corrupt, was accused of fueling the mistrust. Kennedy 'is complicit in dismantling America's public health infrastructure and endangering the nation's health by repeatedly spreading inaccurate health information,' the open letter said, imploring the health chief to change his stance. Since taking office, the nephew of assassinated president John F. Kennedy has made numerous pronouncements that run counter to scientific consensus, particularly about vaccines. This shift toward vaccine skepticism has been denounced by many experts. A petition calling on Congress to impeach Kennedy had gathered more than 12,600 signatures as of Wednesday. The latest open letter from U.S. civil servants, many of whom signed anonymously, comes on the heels of other similar texts backed by federal employees denouncing actions of the Trump administration. Taking such a step was not without risk: nearly 140 staffers at the Environmental Protection Agency who spoke out publicly were placed on leave in last month.
